MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williams, D. P.
Right arrow Articles by Park, B. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williams, D. P.
Right arrow Articles by Park, B. K.

Vol. 58, Issue 1, 207-216, July 2000

Induction of Metabolism-Dependent and -Independent Neutrophil Apoptosis by Clozapine

Dominic P. Williams, Munir Pirmohamed, Dean J. Naisbitt, Jack P. Uetrecht, and Brian K. Park

Department of Pharmacology and Therapeutics, The University of Liverpool, Liverpool, United Kingdom (D.P.W., M.P., D.J.N., B.K.P.); and Faculty of Pharmacy, University of Toronto, Ontario, Canada (J.P.U.)

Clozapine, an atypical antipsychotic used in the treatment of refractory schizophrenia, causes neutropenia and agranulocytosis in 3 and 0.8% of patients, respectively. Clozapine undergoes bioactivation to a chemically reactive nitrenium ion, which has been shown to cause neutrophil cytotoxicity. To define further the mechanism of cell death, we have investigated the toxicity of clozapine, its stable metabolites, and its chemically reactive nitrenium ion to neutrophils and lymphocytes. Clozapine was able to induce neutrophil apoptosis at therapeutic concentrations (1-3 µM) only when it was bioactivated to the nitrenium ion. The parent drug caused apoptosis at supratherapeutic concentrations (100-300 µM) only. Neutrophil apoptosis induced by the nitrenium ion, but not by the parent drug itself, was inhibited by antioxidants and genistein and was accompanied by cell surface haptenation (assessed by flow cytometry) and glutathione depletion. Dual-color flow cytometry showed that neutrophils that were haptenated were the same cells that underwent apoptosis. No apoptosis of lymphocytes was evident with the nitrenium ion or the parent drug, despite the fact that the former caused cell surface haptenation, glutathione depletion, and loss of membrane integrity. Demethylclozapine, the major stable metabolite in vivo, showed a profile that was similar to, although less marked than that observed with clozapine. N-oxidation of clozapine or replacement of the nitrogen (at position 5) by sulfur produced compounds that were entirely nontoxic to neutrophils. In conclusion, the findings of the study expand on potential mechanisms of clozapine-induced cytotoxicity, which may be of relevance to the major forms of toxicity encountered in patients taking this drug.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
LupusHome page
S Vasoo
Drug-induced lupus: an update
Lupus, November 1, 2006; 15(11): 757 - 761.
[Abstract] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
V. Bhatt and A. Saleem
Drug-Induced Neutropenia - Pathophysiology, Clinical Features, and Management
Ann. Clin. Lab. Sci., April 1, 2004; 34(2): 131 - 137.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
N. Berliner, M. Horwitz, and T. P. Loughran Jr.
Congenital and Acquired Neutropenia
Hematology, January 1, 2004; 2004(1): 63 - 79.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics